NeuroSense Therapeutics will announce quarterly earnings Tuesday,June 30th,before market opens. Analysts expect $0.1950 loss per share,with revenues projected at $0.268 million for period.
Tuesday, shares of NeuroSense started at $0.79,down 1.9%. Stock's been on a rollercoaster past year,from low of $0.63 to high of $2.35. Right now, its 50-day moving average is $0.78; 200-day is $0.85. Company has market cap of $25.69 million,price-to-earnings ratio of -1.46,beta of 1.56 .
Insider trading has caught eyes . June 16th,CFO Or Eisenberg bought 250,000 shares at average $0.80,spending $200,000. This upped Eisenberg's stake to 1,504,050 shares,worth about $1.2 million. CEO Alon Ben-Noon did same,buying 250,000 shares,boosting his to 4,534,233 shares,valued around $3.63 million. SEC filings disclosed these transactions.
Insiders own 27.40% of company stock. Institutional investors also shifting positions. Two Sigma Investments LP took new $26,000 position in third quarter. Squarepoint Ops LLC upped stake by 91%,now holding 95,375 shares worth $119,000 after adding 45,450 shares . Jane Street Group LLC bought new stake valued around $54,000 during second quarter. Institutional investors own 1.04% of shares.
Analyst opinions on NeuroSense vary. Weiss Ratings kept “sell (d-)” rating,while Roth MKM started coverage with “buy” rating,targeting $3.00. D. Boral Capital also kept “buy” rating,setting target at $14.00. Now,one analyst rates stock Strong Buy,two as Buy,one as Hold,one as Sell. Average rating “Moderate Buy,”price target $8.50,says MarketBeat.com.
NeuroSense Therapeutics,a clinical-stage biopharma,develops therapies for neurodegenerative,age-related neurological disorders. Mission focuses on unmet needs around protein aggregation,chronic inflammation,cellular senescence in central nervous system. It uses proprietary senotherapeutic platform targeting senescent cells contributing to neurodegeneration…
